CopyFind
По рецепту 🇪🇸 Испания

IBRANCE 75 MG CAPSULAS DURAS

Аналоги IBRANCE 75 MG CAPSULAS DURAS

Найдите более доступные аналоги и дженерики для IBRANCE 75 MG CAPSULAS DURAS.

Ингредиенты

Активный ингредиент: PALBOCICLIB

Неактивные ингредиенты: LACTOSA MONOHIDRATO 55.775 mg


Описание товара

About IBRANCE 75 MG CAPSULAS DURAS

IBRANCE 75 MG CAPSULAS DURAS is a prescription medication containing the active ingredient palbociclib. It is formulated as durable capsules designed for oral administration. The product is intended for use under the supervision of a qualified healthcare professional. Each capsule delivers a precise dose of 75 milligrams of palbociclib, ensuring consistent therapeutic exposure. The capsules are manufactured to meet stringent quality standards and are packaged in a manner that preserves their integrity until the point of use. Patients should follow the dosing schedule prescribed by their clinician and report any concerns promptly. The medication is part of a broader therapeutic strategy for certain types of cancer, and its use is guided by clinical guidelines and individual patient assessment.

Key Benefits & Uses

  • Provides targeted inhibition of cyclin-dependent kinases involved in cell cycle progression.
  • Supports combination therapy with endocrine agents for hormone receptor–positive breast cancer.
  • Offers a structured dosing regimen that can be monitored for efficacy and safety.

Active Ingredient & Action

The active ingredient, palbociclib, selectively blocks cyclin-dependent kinases 4 and 6, which are essential for the transition from the G1 phase to the S phase of the cell cycle. By inhibiting these kinases, palbociclib reduces the proliferation of cancer cells that rely on these pathways for growth. This mechanism of action is central to the therapeutic effect of IBRANCE 75 MG CAPSULAS DURAS in appropriate clinical settings.

Important Notes

IBRANCE 75 MG CAPSULAS DURAS should be taken exactly as directed by a healthcare provider. Patients should be monitored for potential hematologic effects, and dose adjustments may be necessary based on laboratory results. The medication should not be used by individuals with a known hypersensitivity to palbociclib or any component of the formulation. Patients should inform their clinician of all other medications they are taking to avoid possible drug interactions. Storage should be at room temperature, away from moisture and direct sunlight. For further information, consult the prescribing information or speak with a qualified medical professional.

Оценки посетителей

Помогите другим — оцените полезность этой страницы.

Оценок пока нет — будьте первым.